Initial Experience with Temsirolimus in 2nd-, 3rd- and 4th-Line Therapy for Metastatic Renal Cell Cancer: Good Clinical Response

Publisher: Karger

E-ISSN: 1423-0399|86|3|256-260

ISSN: 0042-1138

Source: Urologia Internationalis, Vol.86, Iss.3, 2011-01, pp. : 256-260

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract